熱門資訊> 正文

ALX肿瘤学GAAP每股收益为-0.13美元

2026-08-06 20:14

ALX Oncology press release (ALXO): Q2 GAAP EPS of -$0.13.
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2026, were $153.4 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.

More on ALX Oncology

ALX Oncology: Rebuilding From Critical Setbacks
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
Seeking Alpha’s Quant Rating on ALX Oncology

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。